… and certain TLR agonists appear to promote cell death in tumours. Imiquimod, a TLR7/8
agonist, is used clinically for treating basal cell carcinomas, and in the past TLR3 agonists have …

… cells such as pulmonary neuroendocrine cells that express muscarinic receptors can be …
might also inhibit growth of Merkel Cell Carcinomas, but this again needs to be determined. …

… : Imiquimod was the first TLR agonist approved for treatment of anogenital warts, actinic
keratosis and superficial basal cell carcinoma in humans. Several other agonists of TLRs 4, 7, 8 …

… responses reported in phase 1 trials of the fully human DR5 agonist antibody conatumumab
[one patient with non–small cell lung carcinoma (NSCLC)] and dulanermin (one patient with …

… keratosis, superficial basal cell carcinoma and external genital or perianal warts (condylomata
acuminata).Citation 57 Of note, while both BCG and MPL function as mixed TLR2/TLR4 …

… cell‐mediated immune response. Pre‐clinical studies have indicated the potential of this
TLR‐7 agonist … cell carcinoma syndrome (Gorlin–Goltz syndrome) has also been documented. …

… There is currently heightened interest in the extrinsic apoptosis pathway, with several
proapoptotic receptor agonists (PARAs) in development. The PARAs include the ligand …

… that both an LXR agonist and an XLR inverse agonist could inhibit proliferation and colony
formation and induce apoptosis in ccRCC cells. We observed that the LXR agonist LXR623 …

… agonist) has been evaluated in several tumor types including renal cell carcinoma, glioblastoma,
melanoma, cutaneous T-cell … activity against basal cell carcinoma and melanoma in a …

… bladder carcinoma and the latter against actinic keratosis, superficial basal cell carcinoma,
… Salmonella minnesota that functions as a potent agonist or the TLR4-TICAM1 signaling axis,…